Renovaro Biosciences (RENB) 10-Q 14 Nov 23 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Sep. 30, 2023	Nov. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	001-38758
Entity Registrant Name	Renovaro Biosciences Inc.
Entity Central Index Key	0001527728
Entity Tax Identification Number	45-2559340
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2080 Century Park East
Entity Address, Address Line Two	Suite 906
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90067
City Area Code	(305)
Local Phone Number	918-1980
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RENB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		66,698,144

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Jun. 30, 2023
CURRENT ASSETS:
Cash	$ 523,474	$ 1,874,480
Notes receivable	1,057,875
Prepaids and other assets	324,966	690,925
Total Current Assets	1,906,315	2,565,405
Property and equipment, net	482,510	508,989
OTHER ASSETS:
Definite life intangible assets, net	37,641	39,676
Indefinite life intangible assets	42,611,000	42,611,000
Goodwill	11,640,000	11,640,000
Deposits and other assets	21,742	21,741
Operating lease right-of-use assets	863,598	913,985
Total Other Assets	55,173,981	55,226,402
TOTAL ASSETS	57,562,806	58,300,796
CURRENT LIABILITIES:
Accounts payable – trade	5,421,126	5,296,823
Accrued expenses	797,778	723,173
Other current liabilities		184,733
Current portion of operating lease liabilities	214,061	193,422
Notes payable, net	2,909,987	4,624,947
Convertible notes payable	752,741
Total Current Liabilities	10,095,693	11,023,098
NON-CURRENT LIABILITIES:
Operating lease liabilities, net of current portion	720,801	775,587
Total Non-Current Liabilities	720,801	775,587
Total Liabilities	10,816,494	11,798,685
Commitments and Contingencies
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; Series A Convertible Preferred;1,000,000 shares designated; 561,010 shares issued and outstanding at September 30, 2023 and zero shares issued and outstanding at June 30, 2023	56
Common Stock, par value $0.0001, 100,000,000 shares authorized, 65,698,144 shares issued and outstanding at September 30, 2023, and 63,698,144 shares issued and outstanding at June 30, 2023	6,571	6,371
Additional paid-in capital	300,008,449	290,554,875
Accumulated deficit	(253,204,281)	(244,029,253)
Accumulated other comprehensive loss	(64,483)	(29,882)
Total Stockholders’ Equity	46,746,312	46,502,111
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 57,562,806	$ 58,300,796

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	561,010	0
Preferred stock, shares outstanding	561,010	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	65,698,144	63,698,144
Common stock, shares outstanding	65,698,144	63,698,144

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Expenses
General and administrative	$ 8,290,210	$ 4,556,840
Research and development	566,644	2,605,375
Depreciation and amortization	27,260	28,401
Total Operating Expenses	8,884,114	7,190,616
LOSS FROM OPERATIONS	(8,884,114)	(7,190,616)
Other Income (Expenses)
Loss on extinguishment of debt	(120,018)
Loss on extinguishment of contingent consideration liability		(419,182)
Interest expense	(179,271)	(95,585)
Interest and other income	8,375	5,623
Total Other Income (Expenses)	(290,914)	(509,144)
Loss Before Income Taxes	(9,175,028)	(7,699,760)
Income Tax (Expense) Benefit
NET LOSS	$ (9,175,028)	$ (7,699,760)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net Loss Per Share, Basic	$ (0.14)	$ (0.14)
Net Loss Per Share, Diluted	$ (0.14)	$ (0.14)
Weighted Average Number of Shares Outstanding, Basic	64,480,753	55,099,473
Weighted Average Number of Shares Outstanding, Diluted	64,480,753	55,099,473

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net Loss	$ (9,175,028)	$ (7,699,760)
Other Comprehensive Loss
Foreign Currency Translation, net of taxes	(34,601)	(7,754)
Comprehensive Loss	$ (9,209,629)	$ (7,707,514)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Series A Preferred Stocks [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Jun. 30, 2022		$ 5,302	$ 276,989,179	$ (204,345,197)	$ (30,436)	$ 72,618,848
Beginning Balance, Shares at Jun. 30, 2022		53,007,082
Stock issued pursuant to warrants exercised		$ 125	1,624,875			1,625,000
Stock issued pursuant to warrants exercised, shares		1,250,000
Shares issued for earn-out		$ 125	2,762,375			2,762,500
Shares issued for Earn-out, shares		1,250,000
Stock-based compensation			1,026,008			1,026,008
Net loss				(7,699,760)		(7,699,760)
Foreign currency translation adjustment					(7,754)	(7,754)
Ending balance, value at Sep. 30, 2022		$ 5,552	282,402,437	(212,044,957)	(38,190)	70,324,842
Ending Balance, Shares at Sep. 30, 2022		55,507,082
Beginning balance, value at Jun. 30, 2023		$ 6,371	290,554,875	(244,029,253)	(29,882)	46,502,111
Beginning Balance, Shares at Jun. 30, 2023		63,698,144
Issuance of preferred stock and warrants in private placement	$ 28		1,999,972			2,000,000
Issuance of preferred stock and warrants in private placement, shares	280,505
Issuance of preferred stock and warrants for conversion of $2 million Note	$ 28		1,999,973			2,000,001
Issuance of preferred stock and warrants for conversion $2 million Note, shares	280,505
Restricted shares issued for services rendered		$ 200	4,469,800			4,470,000
Restricted shares issued for services rendered, shares		2,000,000
Stock-based compensation			983,829			983,829
Net loss				(9,175,028)		(9,175,028)
Foreign currency translation adjustment					(34,601)	(34,601)
Ending balance, value at Sep. 30, 2023	$ 56	$ 6,571	$ 300,008,449	$ (253,204,281)	$ (64,483)	$ 46,746,312
Ending Balance, Shares at Sep. 30, 2023	561,010	65,698,144

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,175,028)	$ (7,699,760)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization	27,260	28,401
Loss on extinguishment of debt	120,018
Loss on extinguishment of contingent consideration liability		419,182
Stock based compensation expense	983,829	1,026,008
Restricted shares for services rendered	4,470,000
Amortization of discount of notes payable	167,765	74,621
Changes in assets and liabilities:
Other receivables		(3,988)
Prepaid expenses/deposits	411,352	239,703
Accounts payable	124,303	3,280,877
Accrued expenses	77,055	10,783
Other current liabilities		(18,520)
Operating leases, net	16,239	(10,981)
NET CASH USED IN OPERATING ACTIVITIES	(2,777,207)	(2,653,674)
CASH FLOWS FROM INVESTING ACTIVITIES:
Notes receivable	(1,057,875)
NET CASH USED IN INVESTING ACTIVITIES	(1,057,875)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible promissory notes	750,000
Repayment of finance agreement	(187,183)	(166,625)
Proceeds from private placement	2,000,000
Proceeds from exercise of warrants		1,625,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,562,817	1,458,375
Effect of exchange rates on cash	(78,741)	(4,925)
NET CHANGE IN CASH	(1,351,006)	(1,200,224)
CASH, BEGINNING OF PERIOD	1,874,480	9,172,142
CASH, END OF PERIOD	523,474	7,971,918
Cash paid during the period for:
Interest	5,256	30,332
Income Taxes
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES
Conversion of note payable for issuance of preferred stock	2,000,001
Common shares issued for contingent earn out liability		2,762,500
Debt discount related to convertible promissory notes	$ 39,474

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Going Concern 253,204,281 Basis of Presentation Consolidation Accounting Estimates Functional Currency & Foreign Currency Translation Cash and Cash Equivalents 144,568 1,526,990 Property and Equipment Intangible Assets Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application. Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill th Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $ 18,960,000 The carrying value of IPR&D and goodwill at September 30, 2023, were $ 42,611,000 11,640,000 Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 6.) Research and Development Expenses 566,644 2,605,375 Income Taxes Loss Per Share 17,136,596 4,495,477 Fair Value of Financial Instruments 0 419,182 Stock Options and Restricted Share Units Stock-Based Compensation 983,829 1,026,008 Recently Adopted Accounting Pronouncements

GOING CONCERN

GOING CONCERN	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 — GOING CONCERN The Company’s consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of $ 9,175,028 7,699,760 523,474 253,204,281

NOTES RECEIVABLE

NOTES RECEIVABLE	3 Months Ended
	Sep. 30, 2023
Notes Receivable
NOTES RECEIVABLE	NOTE 3 — NOTES RECEIVABLE On August 11, 2023, and August 18, 2023, the Company entered into two Promissory Notes (“Notes”) in the amounts $ 550,000 500,000 1.05 million GEDi Cube Intl Ltd. 6 7,875 1,057,875

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following: Summary of property and equipment Useful Life September 30, 2023 June 30, 2023 Lab Equipment and Instruments 4 7 $ 576,298 $ 576,298 Leasehold Improvements 10 224,629 224,629 Furniture, Fixtures and Equipment 4 7 172,861 172,861 Total 973,788 973,788 Less Accumulated Depreciation (491,278 ) (464,799 ) Net Property and Equipment $ 482,510 $ 508,989 Depreciation expense amounted to $ 26,479 26,915

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 — INTANGIBLE ASSETS At September 30, 2023, and June 30, 2023, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $ 37,641 39,676 781 1,486 At September 30, 2023, and 2022, indefinite life intangible assets consisted of a license agreement classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible asset provides economic benefit, and goodwill. At September 30, 2023, and June 30, 2023, definite and indefinite-life intangible assets consisted of the following: Schedule of intangible assets Useful Life June 30, Period Change Effect of Currency Translation September 30, Definite Life Intangible Assets Patents 20 $ 290,936 $ — $ (9,356 ) $ 281,580 Less Accumulated Amortization (251,260 ) (781 ) 8,102 (243,939 ) Net Definite-Life Intangible Assets $ 39,676 $ (781 ) $ (1,254 ) $ 37,641 Indefinite Life Intangible Assets License Agreement $ 42,611,000 — — $ 42,611,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 54,251,000 — — $ 54,251,000 Expected future amortization expense is as follows: Schedule of expected future amortization expense Year ending June 30, 2024 $ 7,059 2025 10,194 2026 10,194 2027 10,194 Total $ 37,641 During February 2018, the Company acquired a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. Because the HIV License Agreement is considered an IPR&D intangible asset it is classified as an indefinite life asset that is tested annually for impairment. Impairment – Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a quantitative assessment and determines if it is more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset. The results of the quantitative assessment indicated that the carrying value of the license acquired as an IPR&D asset exceeded its fair value, due to the sublicensing of RENB-HV01, which required a different valuation approach and changes in other factors impacting the fair value of the asset as of June 30, 2023, which resulted in an impairment adjustment of $ 18,960,000

LEASES

LEASES	3 Months Ended
	Sep. 30, 2023
Leases
LEASES	NOTE 6 — LEASES Operating Leases On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized. On June 19, 2018, Renovaro entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. Sublease Agreement The Company identified and assessed the following significant assumptions in recognizing the right-of-use asset and corresponding liabilities: Expected lease term 3.92 Incremental borrowing rate 4.03 Lease and non-lease components Below are the lease commitments for the next 5 years: Schedule of lease commitments Year Ending June 30 th Lease Expense 2024 185,403 2025 253,384 2026 260,985 2027 268,815 2028 45,021 Sub-total 1,013,608 Less imputed interest (78,746 ) Total $ 934,862 Sublease Agreement On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022. In accordance with ASC Topic 842, the Company treated the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease was classified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. On April 18, 2023, the Company entered into a sublease termination agreement with the Subtenant, whereby the Subtenant and the Company agreed to terminate the sublease effective as of April 30, 2023. The Subtenant agreed to pay the Company $ 139,460 35,540 175,000 The Company recognized operating income from the sublease on a straight-line basis in its statements of operations over the sublease term. For the three months ended September 30, 2023, and 2022, the net operating lease expenses were as follows: Schedule of net operating lease expenses Three Months Ended September 30, 2023 2022 Operating Lease Expense $ 68,743 $ 43,930 Sublease Income — (53,310 ) Total Net Lease Expense (Income) $ 68,743 $ (9,380 ) Lease expense (income) charged to general and administrative expenses for the three months ended September 30, 2023, and 2022, amounted to $ 68,743 (9,380 61,223 144,461

DEBT

DEBT	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
DEBT	NOTE 7 — DEBT Convertible Notes Payable — Between September 5, 2023, and September 29, 2023, the Company entered into Subscription Agreements with two investors (the “Investors”) to purchase 5 789,474 750,000 5 12 September 5, 2024 The 2023 Notes are subject to mandatory conversion (“Mandatory Conversion”) in the event the Company closes an offering of its Common Stock and receives gross proceeds of not less than $ 10,000,000 95 4.50 4.50 The 2023 Notes will be accounted for under ASC 470-20, and all proceeds received from the issuance will be recognized as a liability on the balance sheet net of discount. During the three months ended September 30, 2023, the Company issued the 2023 Notes in an aggregate principal amount of $ 789,474 750,000 5 39,474 1,250,000 For the three months ended September 30, 2023, discount amortization of $ 2,741 6,250 752,741 On February 6, 2020, the Company issued two Convertible Notes (the “Convertible Notes”) to Paseco ApS (the “Holder”), a Danish limited company and an existing stockholder of the Company each with a face value amount of $ 600,000 February 6, 2023 6 The conversion price was equal to $12.00 per share of common stock. The Holder did not exercise its conversion right and the conversion feature expired on February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash. All proceeds received from the issuance were recognized as a liability on the balance sheet. Effective December 30, 2022 (the “Effective Date”), the Company amended and restated the Convertible Notes (the “Amended and Restated Secured Notes”). Pursuant to the Amended and Restated Secured Notes, the due date was extended to February 28, 2024 12 198,439 29,419 169,020 1.03 1,200,000 204,392 174,090 30,302 the Holder notified the Company that it wished to elect to exercise its conversion right triggered by a private placement. Therefore, all outstanding $ 1,200,000 1,132,075 As of September 30, 2023 and 2022, the Company recorded accrued interest in the amount of zero 0 12,030 0 18,182 0 Note Payable On March 30, 2020 (the “Issuance Date”), the Company issued a Promissory Note in the principal amount of $ 5,000,000 November 30, 2021 6 188,485 501,370 493,192 493,192 On February 11, 2021, the Company entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 6 74,054 298,178 On May 17, 2022, the Company entered into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 6 12 47,115 299,178 Effective December 30, 2022, the Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company’s obligations under the Promissory Note were secured by the Security Agreement. To secure the Company’s obligations under each of the Amended and Restated Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral. On June 12, 2023, the Holder notified the Company that it wanted to apply the Interest Payment due to it towards the Company’s next private placement. Therefore, on June 26, 2023, in conjunction with the Company’s private placement, the Company issued (i) 567,588 283,794 0.53 300,822 On July 31, 2023, the Company and the Holder agreed to amend the Promissory Note (the “Fourth Amendment”) to provide the Holder with limited conversion rights in connection with the Company’s next private placement. Per the terms of the Fourth Amendment, the Holder could elect to convert $2 million of the outstanding principal balance of the Promissory Note into the Units being offered in the private placement at a price per Unit being paid by the investors in the private placement (the “Conversion Right”). On August 1, 2023, the Holder notified the Company of its election to exercise the Conversion Right. As a result, $2 million of the outstanding principal balance of the Promissory Note was converted into 280,505 Units at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible Preferred Stock of the Company and (ii) Warrants to purchase an aggregate of 1,402,525 shares of common stock with an exercise price of $0.65 per share. The Series A Convertible Preferred Stock acquired by the Holder is initially convertible into 2,805,050 shares of common stock. A $3 million principal balance remains outstanding under the Promissory Note after the forgoing conversion. The Company concluded that in accordance with ASC 470-20-40-4, the difference between the fair value of the Preferred Shares and warrants and the carrying value of the portion of the Note being converted should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded in Other Income/Loss in the Statement of Operations. For the three months ended September 30, 2023 and 2022, discount amortization of $ 165,023 74,621 2,909,987 Finance Agreement On November 30, 2022, the Company entered into a premium finance agreement (the “Agreement”) related to insurance, which resulted in a prepaid expense with a principal amount of $ 1,139,875 at 6.69 % interest per annum. 96,220 after a down payment of $ 300,000 For the three months ended September 30, 2023 and 2022 the Company made payments of $ 187,183 and $ 166,625 , respectively. 5,256 2,782 Total interest expense recorded for the three months ended September 30, 2023 and 2022, was $ 179,271 95,585

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 — STOCKHOLDERS’ EQUITY Preferred Stock 10,000,000 0.0001 1,000,000 0 561,010 0 Voting — Dividends — Liquidation Rights — Conversion Rights — Common Stock 100,000,000 0.0001 65,698,144 63,698,144 Voting — Dividends — Liquidation Rights — Purchase Agreement with Lincoln Park Capital On June 20, 2023, the Company entered into a purchase agreement (the “2023 Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $ 20,000,000 In consideration for entering into the 2023 Purchase Agreement, the Company issued 696,021 During the three months ended September 30, 2023, we did not sell any shares of common stock to Lincoln Park under the Purchase Agreement. Preferred Stock Issuances On August 1, 2023, the Company closed a private placement of 280,505 Units Preferred Stock Warrant Securities 7.13 2,000,000 280,505 2,000,000 The Company issued an aggregate of 561,010 5,610,100 2,805,050 0.65 Common Stock Issuances Between July 28, 2023 and September 28, 2023, the Company issued 2,000,000 Acquisition of Renovaro Denmark — 17,414 167,639 0 Stock-based Compensation The Company recognizes compensation costs for stock option awards to employees and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair values of the stock options granted using the Black-Scholes option-pricing model are as follows in the three months ended September 30, 2023: Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted Renovaro Expected term (in years) 5.0 5.5 Volatility 84.33 106.29 Risk free interest rate 3.12 4.62 Dividend yield 0 The Company recognized stock-based compensation expense related to the options of $ 983,829 1,026,008 1,305,630 Plan Options On February 6, 2014, the Board adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 On October 30, 2019, the Board approved and on October 31, 2019, the Company’s stockholders adopted its 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company’s common stock reserved and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered, or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan. Effective July 21, 2023, the Company adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan replaced the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject to and will be paid under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2023 Plan. The Company granted options to purchase 0 350,000 During the three months ended September 30, 2023 and 2022, respectively, the Company granted options to purchase 0 184,800 18,960 0 During the three months ended September 30, 2023 and 2022, the Company granted options to purchase 0 73,200 During the three months ended September 30, 2023 and 2022, the Company granted options to purchase 219,106 50,958 During the three months ended September 30, 2023 and 2022, the Company granted options to purchase 26,000 0 All of the above options are exercisable at the market price of the Company’s common stock on the date of the grant. To date the Company has granted options under the 2014, 2019 and 2023 Plans (“Plan Options”) to purchase 5,134,285 6,047,409 A summary of the status of the Plan Options outstanding at September 30, 2023, is presented below: Schedule of stock options outstanding Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 0.45 4.50 1,689,821 8.77 $ 2.05 659,481 7.96 $ 2.80 $ 4.51 6.50 2,503,102 7.36 $ 4.89 1,834,769 7.20 $ 5.01 $ 6.51 12.00 803,393 6.95 $ 8.02 694,016 6.75 $ 7.98 Total 4,996,317 7.77 $ 4.44 3,188,267 7.26 $ 5.20 A summary of the status of the Plan Options at September 30, 2023, and changes since July 1, 2023, are presented below: Summary of stock option activity Shares Weighted Average Exercise Average Remaining Life Weighted Average Intrinsic Outstanding at beginning of period 4,401,211 $ 4.78 7.82 $ — Granted 595,106 $ 1.89 $ Exercised — $ — — $ Forfeited — $ — — $ Expired/Canceled — $ — — $ Outstanding at end of period 4,996,317 $ 4.44 7.77 $ — Exercisable at end of period 3,188,267 $ 5.20 7.26 $ 3,409,891 At September 30, 2023, the Company had 3,188,267 3,409,891 Common Stock Purchase Warrants A summary of the warrants outstanding at September 30, 2023, and changes since July 1, 2023, are presented below: Summary of common stock purchase warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at beginning of period 3,548,302 $ 0.73 4.80 Granted 2,805,050 $ 0.65 — Exercised — $ — — Cancelled/Expired — $ — — Outstanding and exercisable at end of period 6,353,352 $ 0.70 4.63

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 — COMMITMENTS AND CONTINGENCIES Commitments On July 9, 2018, the Company entered into a consulting agreement with G-Tech Bio, LLC, a California limited liability company (“G-Tech”) to assist the Company with the development of the gene therapy and cell therapy modalities for the prevention, treatment, and amelioration of HIV in humans, and with the development of a genetically enhanced Dendritic Cell for use as a wide spectrum platform for various diseases (including but not limited to cancers and infectious diseases) (the “G-Tech Agreement”). G-Tech was entitled to consulting fees for 20 months, with a monthly consulting fee of not greater than $ 130,000 On January 31, 2020, the Company entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company, G-Tech, and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”) (collectively the “Licensors”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections. The HBV License Agreement states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $ 1.2 2 1.2 The cash funding for research costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made after January 31, 2022. The Company paid zero under the HBV License Agreement in the three months ended September 30, 2023, and 2022. The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section below). On April 18, 2021, the Company entered into a Statement of Work and License Agreement (the “License Development Agreement”), by and among the Company, G-Tech and SRI (collectively, the “Licensors”), whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development License”) to research, develop, and commercialize certain formulations which are aimed at preventing and treating pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (the “Prevention and Treatment”). The Development License Agreement was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides for an up-front payment of $ 10,000,000 760,000 The Development License Agreement provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty to G-Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license (see Contingencies sub-section below). On August 25, 2021, the Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”) with Serhat Gümrükcü and SRI (collectively, the “Licensors”) whereby the Licensors granted the Company an exclusive, worldwide, perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application, to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use, offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $ 600,000 600,000 G-Tech and SRI are controlled by Anderson Wittekind, a stockholder of the Company. Shares held for non-consenting shareholders 17,414 0 Service Agreements – The Company maintains employment agreements with other staff in the ordinary course of business. Stock Purchase Agreement with GEDi Cube Intl Ltd. Purchase Agreement GEDi Cube 100 Sellers Transaction At the effective time of the Transaction (the “ Effective Time GEDi Cube Share Renovaro Shares Closing Consideration Earnout Shares Each of the Company and GEDi Cube agreed, subject to certain exceptions with respect to unsolicited proposals, not to directly or indirectly solicit competing acquisition proposals or to enter into discussions concerning, or provide confidential information in connection with, any unsolicited alternative acquisition proposals. The completion of the Transaction is subject to the satisfaction or waiver of customary closing conditions, including: (i) adoption of the Purchase Agreement by holders of all of the outstanding GEDi Cube Shares, (ii) approval of the issuance of Renovaro Shares in connection with the Transaction by a majority of the votes cast at the shareholder meeting of the Company, (iii) absence of any court order or regulatory injunction prohibiting completion of the Transaction, (iv) subject to specified materiality standards, the accuracy of the representations and warranties of the other party, (v) the authorization for listing of Renovaro Shares to be issued in the Transaction on the Nasdaq, (vi) compliance by the other party in all material respects with its covenants, and (vii) the entry by the parties into a registration rights agreement, to become effective as of the Effective Time, pursuant to which the Company will provide registration rights to the Sellers with respect to (a) the Renovaro Shares issued to the Sellers as Closing Consideration at the Effective Time and (b) any Earnout Shares that they receive after the Closing. The Company and GEDi Cube each made customary representations and warranties in the Purchase Agreement. The Purchase Agreement also contains customary covenants and agreements, including covenants and agreements relating to (i) the conduct of each of the Company’s and GEDi Cube’s business between the date of the signing of the Purchase Agreement and the closing date of the Transaction and (ii) the efforts of the parties to cause the Transaction to be completed. The Purchase Agreement contains certain termination rights for both the Company and GEDi Cube. Contingencies Securities Class Action Litigation Federal Derivative Litigation State Derivative Litigation On October 21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gümrükcü, William Anderson Wittekind (“Wittekind”), G Tech, SG & AW Holdings, LLC, and SRI. The Complaint alleges that the defendants engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the defendants’ conduct, the Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.” On April 21, 2023, defendants Wittekind, G Tech, SG & AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company’s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening deadlines. We will continue to pursue our claims against these defendants. On March 1, 2021, the Company’s former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Renovaro BioSciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The allegations in the Complaint relate to an earlier action filed by the Company and Renovaro BioSciences Denmark ApS in the Vermont Superior Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company’s motion to dismiss, dismissing the abuse of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29, 2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24, 2023, the court denied the motion for summary judgment. On September 7, 2023, the Company moved for reconsideration of the court’s order. The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim. On June 7, 2023, Weird Science LLC (“Weird Science”), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the “Trusts”) (collectively, “Plaintiffs”) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. Plaintiffs allege that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science, and RS Group ApS (the “Investor Rights Agreement”). According to the Verified Complaint, the Investor Rights Agreement required the Company to (i) notify all “Holders” of “Registrable Securities” at least 30 days prior to filing a registration statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs allege that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration statements filed by the Company on July 13, 2020 and February 11, 2022. Plaintiffs seek compensatory damages, pre- and post-judgment interest, costs, and attorneys’ fees. The Company denies Plaintiffs’ allegations and intends to vigorously defend against the claim. On August 24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company’s books and records (the “Demand”) pursuant to Delaware General Corporation Law, § 220 (“Section 220”). The Demand seeks the Company’s books and records in connection with various issues identified in the Demand. The Company takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with those obligations.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 — RELATED PARTY TRANSACTIONS On August 1, 2023, RS Bio ApS, a Danish entity, purchased in the Private Placement 70,126 7.13 500,000 Mr. Rene Sindlev, the Chairman of the Company’s Board of Directors, holds the sole voting and disposition power of the shares owned by RS Bio ApS. The Board of Directors (excluding Mr. Sindlev) approved the participation of certain officers and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement On August 1, 2023, Paseco ApS, a Danish entity, in connection with the Private Placement, converted $ 2,000,000 280,505 7.13 The Company currently has a consulting agreement with Paseco for business advisory services since December of 2019. For the three months ended September 30, 2023 the Company issued 1,000,000

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 — SUBSEQUENT EVENTS On October 10, 2023, the Board of Directors (the “Board”) of Renovaro Biosciences Inc., a Delaware corporation (the “Company”), appointed Avram Miller to the Board, effective October 11, 2023, to fill a vacancy. Mr. Miller will serve until the Company’s 2024 Annual Meeting of Stockholders or until his successor has been duly elected and qualified. In addition to Mr. Miller’s appointment to the Board, Mr. Miller, the co-founder of Intel Capital, entered into an advisory agreement with the Company (the “Advisory Agreement”), pursuant to which Mr. Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation, business development, minority investments and licensing arrangements, among others. As compensation for these services, the Company will issue Mr. Miller 1,000,000 166,667 444,444 388,889 Between October 2, 2023, and October 5, 2023, the Company entered into Subscription Agreements with three investors (the “Investors”) to purchase 5 1,315,789 1,250,000 5 12 September 5, 2024

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Business	Business
Going Concern	Going Concern 253,204,281
Basis of Presentation	Basis of Presentation
Consolidation	Consolidation
Accounting Estimates	Accounting Estimates
Functional Currency & Foreign Currency Translation	Functional Currency & Foreign Currency Translation
Cash and Cash Equivalents	Cash and Cash Equivalents 144,568 1,526,990
Property and Equipment	Property and Equipment
Intangible Assets	Intangible Assets Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, “Goodwill and Other Intangible Assets”. Intangible assets are recorded at cost. Patent costs consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not be issued, the related remaining capitalized patent costs are charged to expense. Intangible assets are amortized on a straight-line basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application. Indefinite life intangible assets include license agreements and goodwill. The Company accounts for indefinite life intangible assets in accordance with ASC 350, “Goodwill and Other Intangible Assets”. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment, as well as whenever events or changes in circumstances indicate the carrying value may not be recoverable.
Goodwill	Goodwill th
Impairment of Goodwill and Indefinite Lived Intangible Assets	Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite-lived intangible assets, such as licenses acquired as an IPR&D asset, on an annual basis we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value. Therefore, the Company recorded an impairment loss of $ 18,960,000 The carrying value of IPR&D and goodwill at September 30, 2023, were $ 42,611,000 11,640,000
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values.
Leases	Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right of use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, insurance, and taxes, which vary based on future outcomes, and thus are recognized in general and administrative expenses when incurred (see Note 6.)
Research and Development Expenses	Research and Development Expenses 566,644 2,605,375
Income Taxes	Income Taxes
Loss Per Share	Loss Per Share 17,136,596 4,495,477
Fair Value of Financial Instruments	Fair Value of Financial Instruments 0 419,182
Stock Options and Restricted Share Units	Stock Options and Restricted Share Units
Stock-Based Compensation	Stock-Based Compensation 983,829 1,026,008
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Summary of property and equipment	Summary of property and equipment Useful Life September 30, 2023 June 30, 2023 Lab Equipment and Instruments 4 7 $ 576,298 $ 576,298 Leasehold Improvements 10 224,629 224,629 Furniture, Fixtures and Equipment 4 7 172,861 172,861 Total 973,788 973,788 Less Accumulated Depreciation (491,278 ) (464,799 ) Net Property and Equipment $ 482,510 $ 508,989

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Schedule of intangible assets Useful Life June 30, Period Change Effect of Currency Translation September 30, Definite Life Intangible Assets Patents 20 $ 290,936 $ — $ (9,356 ) $ 281,580 Less Accumulated Amortization (251,260 ) (781 ) 8,102 (243,939 ) Net Definite-Life Intangible Assets $ 39,676 $ (781 ) $ (1,254 ) $ 37,641 Indefinite Life Intangible Assets License Agreement $ 42,611,000 — — $ 42,611,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 54,251,000 — — $ 54,251,000
Schedule of expected future amortization expense	Schedule of expected future amortization expense Year ending June 30, 2024 $ 7,059 2025 10,194 2026 10,194 2027 10,194 Total $ 37,641

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Sep. 30, 2023
Leases
Schedule of lease commitments	Schedule of lease commitments Year Ending June 30 th Lease Expense 2024 185,403 2025 253,384 2026 260,985 2027 268,815 2028 45,021 Sub-total 1,013,608 Less imputed interest (78,746 ) Total $ 934,862
Schedule of net operating lease expenses	Schedule of net operating lease expenses Three Months Ended September 30, 2023 2022 Operating Lease Expense $ 68,743 $ 43,930 Sublease Income — (53,310 ) Total Net Lease Expense (Income) $ 68,743 $ (9,380 )

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted	Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted Renovaro Expected term (in years) 5.0 5.5 Volatility 84.33 106.29 Risk free interest rate 3.12 4.62 Dividend yield 0
Schedule of stock options outstanding	Schedule of stock options outstanding Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 0.45 4.50 1,689,821 8.77 $ 2.05 659,481 7.96 $ 2.80 $ 4.51 6.50 2,503,102 7.36 $ 4.89 1,834,769 7.20 $ 5.01 $ 6.51 12.00 803,393 6.95 $ 8.02 694,016 6.75 $ 7.98 Total 4,996,317 7.77 $ 4.44 3,188,267 7.26 $ 5.20
Summary of stock option activity	Summary of stock option activity Shares Weighted Average Exercise Average Remaining Life Weighted Average Intrinsic Outstanding at beginning of period 4,401,211 $ 4.78 7.82 $ — Granted 595,106 $ 1.89 $ Exercised — $ — — $ Forfeited — $ — — $ Expired/Canceled — $ — — $ Outstanding at end of period 4,996,317 $ 4.44 7.77 $ — Exercisable at end of period 3,188,267 $ 5.20 7.26 $ 3,409,891
Summary of common stock purchase warrants outstanding	Summary of common stock purchase warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at beginning of period 3,548,302 $ 0.73 4.80 Granted 2,805,050 $ 0.65 — Exercised — $ — — Cancelled/Expired — $ — — Outstanding and exercisable at end of period 6,353,352 $ 0.70 4.63

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Accounting Policies [Abstract]
Accumulated deficit	$ 253,204,281		$ 244,029,253
Cash held in financial institutions	144,568		1,526,990
Goodwill impairment loss			18,960,000
IPR&D	42,611,000		42,611,000
Goodwill	11,640,000		$ 11,640,000
Research and development expense	$ 566,644	$ 2,605,375
Potential dilutive shares	17,136,596	4,495,477
Contingent consideration liability	$ 0	$ 419,182
Stock-based compensation	$ 983,829	$ 1,026,008

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 9,175,028	$ 7,699,760
Cash and cash equivalents	523,474		$ 1,874,480
Accumulated deficit	$ 253,204,281		$ 244,029,253

NOTES RECEIVABLE (Details Narra

NOTES RECEIVABLE (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Aug. 18, 2023	Aug. 11, 2023
Notes Receivable
Promissory notes amount			$ 500,000	$ 550,000
Promissory notes amount total	$ 1,050,000
Accrued interest rate	6%
Accrued interest value	$ 7,875
Notes receivable value	$ 1,057,875

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Total	$ 973,788	$ 973,788
Less Accumulated Depreciation	(491,278)	(464,799)
Net Property and Equipment	482,510	508,989
Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Total	$ 576,298	576,298
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Total	$ 224,629	224,629
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	$ 172,861	$ 172,861
Minimum [Member] | Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Minimum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Maximum [Member] | Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Maximum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 26,479	$ 26,915

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Period Change
Effect of Currency Translation	(1,254)
Definite-life intangible assets	37,641	$ 39,676
Definite-life intangible assets period change	(781)
Indefinite Life Intangible Assets	$ 54,251,000	54,251,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Definite-life intangible assets	$ 281,580	290,936
Period Change
Effect of Currency Translation	(9,356)
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Period Change	(781)
Effect of Currency Translation	8,102
Accumulated Amortization	(243,939)	(251,260)
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Period Change
Indefinite Life Intangible Assets	42,611,000	42,611,000
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Period Change
Indefinite Life Intangible Assets	$ 11,640,000	$ 11,640,000

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL (Details 1) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 7,059
2025	10,194
2026	10,194
2027	10,194
Total	$ 37,641	$ 39,676

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Indefinite-Lived Intangible Assets [Line Items]
Definite-life intangible assets	$ 37,641		$ 39,676
Amortization expense	$ 781	$ 1,486
In Process Research and Development [Member]
Indefinite-Lived Intangible Assets [Line Items]
Impairment loss			$ 18,960,000

LEASES (Details)

LEASES (Details)	Sep. 30, 2023 USD ($)
Leases
2024	$ 185,403
2025	253,384
2026	260,985
2027	268,815
2028	45,021
Less imputed interest	1,013,608
Less imputed interest	(78,746)
Total	$ 934,862

LEASES (Details 1)

LEASES (Details 1) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases
Operating Lease Expense	$ 68,743	$ 43,930
Sublease Income		(53,310)
Total Net Lease Expense (Income)	$ 68,743	$ (9,380)

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)					3 Months Ended
	Apr. 30, 2023	Jun. 20, 2022	Jun. 19, 2018	Nov. 13, 2017	Sep. 30, 2023	Sep. 30, 2022
Leases
Lease premises, description			On June 19, 2018, Renovaro entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.	On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized.
Weighted-average remaining term					3 years 11 months 1 day
Weighted-average discount rate					4.03%
Sublease agreement description		On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
Lease payment	$ 139,460
Security deposit	35,540
Termination fee	$ 175,000
General and administrative expenses					$ 68,743	$ (9,380)
Operating leases					$ 61,223	$ 144,461

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)								3 Months Ended
	Aug. 01, 2023	Jun. 26, 2023	Dec. 30, 2022	Nov. 30, 2022	May 17, 2022	Mar. 30, 2020	Feb. 06, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 29, 2023	Sep. 05, 2023	Feb. 11, 2021
Debt Instrument [Line Items]
Original issue discount percentage								5%		5%	5%
Principal amount								$ 789,474		$ 789,474	$ 789,474
Received total in gross proceeds								$ 750,000
Bear interest percentage								12%
Maturity date								Sep. 05, 2024
Common Stock and receives gross proceeds								$ 10,000,000
Offering price per share percentage								95%
Floor of per share								$ 4.50
Discount amount								$ 39,474
Additional principal amount								1,250,000
Discount amortization								2,741
Accrued interests expenses								6,250
Debt net of discount								752,741
Prepayment shares			169,020
Number of shares issued, value			$ 204,392
Prepaid interest			174,090
Accrued interest amount			$ 30,302					0	$ 12,030
Stock issued for debt conversion								1,200,000
Interest Expense								179,271	95,585
Amended and restated secured notes balance								0
Issuance of common stock					$ 299,178
Interest at the fixed rate				6.69%
Number of shares issued					47,115
Proceeds from private placement	$ 500,000							2,000,000
Debt Instrument, Annual Principal Payment				$ 1,139,875
Monthly installments amount				96,220
Down payment amount				$ 300,000				187,183	166,625
Total interest expense								5,256	2,782
interest expense								$ 179,271	95,585
Warrant [Member]
Debt Instrument [Line Items]
Stock issued for debt conversion, shares								1,132,075
Convertible Notes Payables [Member]
Debt Instrument [Line Items]
Principal amount							$ 600,000
Maturity date							Feb. 06, 2023
Interest rate							6%
Stock price			$ 1.03
Interest Expense								$ 0	18,182
Secured Notes [Member]
Debt Instrument [Line Items]
Maturity date			Feb. 28, 2024
Interest rate			12%
Issuance of shares			198,439
Number of shares issued			29,419
Obligation value			$ 1,200,000
Note Payable [Member]
Debt Instrument [Line Items]
Principal amount						$ 5,000,000
Maturity date						Nov. 30, 2021
Interest rate						6%
Stock issued for debt conversion						$ 501,370
Stock issued for debt conversion, shares						188,485
Issuance of common stock						$ 493,192
Promissory Note [Member]
Debt Instrument [Line Items]
Maturity date					Nov. 30, 2023
Discount amortization								165,023	$ 74,621
Debt net of discount								$ 2,909,987
Interest at the fixed rate												6%
Number of shares issued												74,054
Market price												$ 298,178
Promissory Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest at the fixed rate					6%
Promissory Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest at the fixed rate					12%
Private Placement [Member]
Debt Instrument [Line Items]
Original issue discount percentage								5%
Received total in gross proceeds								$ 750,000
Number of shares issued	70,126
Private Placement [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Number of shares issued		567,588
Warrants purchased		$ 283,794
Warrant purchase price		$ 0.53
Proceeds from private placement		$ 300,822

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - Enochian Biosciences [Member]	3 Months Ended
	Sep. 30, 2023
Dividend yield	0%
Minimum [Member]
Expected term (in years)	5 years
Volatility	84.33%
Risk free interest rate	3.12%
Maximum [Member]
Expected term (in years)	5 years 6 months
Volatility	106.29%
Risk free interest rate	4.62%

STOCKHOLDERS' EQUITY (Details 1

STOCKHOLDERS' EQUITY (Details 1) - Share-Based Payment Arrangement, Option [Member] - $ / shares	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023
Option Indexed to Issuer's Equity [Line Items]
Number share option outstanding	4,996,317	4,401,211
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 9 months 7 days
Options Outstanding, Weighted Average Exercise Price	$ 4.44	$ 4.78
Options Exercisable	3,188,267
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 3 months 3 days
Options Exercisable, Weighted Average Exercise Price	$ 5.20
Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Number share option outstanding	1,689,821
Options Outstanding, Weighted Average Remaining Contractual Life (years)	8 years 9 months 7 days
Options Outstanding, Weighted Average Exercise Price	$ 2.05
Options Exercisable	659,481
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 11 months 15 days
Options Exercisable, Weighted Average Exercise Price	$ 2.80
Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Number share option outstanding	2,503,102
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 4 months 9 days
Options Outstanding, Weighted Average Exercise Price	$ 4.89
Options Exercisable	1,834,769
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price	$ 5.01
Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Number share option outstanding	803,393
Options Outstanding, Weighted Average Remaining Contractual Life (years)	6 years 11 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 8.02
Options Exercisable	694,016
Options Exercisable, Weighted Average Remaining Contractual Life (years)	6 years 9 months
Options Exercisable, Weighted Average Exercise Price	$ 7.98
Minimum [Member] | Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	0.45
Minimum [Member] | Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	4.51
Minimum [Member] | Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	6.51
Maximum [Member] | Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	4.50
Maximum [Member] | Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	6.50
Maximum [Member] | Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices	$ 12

STOCKHOLDERS' EQUITY (Details 2

STOCKHOLDERS' EQUITY (Details 2) - Share-Based Payment Arrangement, Option [Member]	3 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding at beginning of period | shares	4,401,211
Weighted Average Exercise Price, Outstanding at beginning of period | $ / shares	$ 4.78
Weighted Average remaining life	7 years 9 months 25 days
Weighted Average Intrinsic Value, Outstanding at beginning of period | $
Granted | shares	595,106
Weighted average exercise price, Granted | $ / shares	$ 1.89
Exercised | shares
Weighted average exercise price, Exercised | $ / shares
Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Cancelled/Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Options Outstanding at end of period | shares	4,996,317
Weighted Average Exercise Price, Outstanding at ending of period | $ / shares	$ 4.44
Weighted Average remaining life	7 years 9 months 7 days
Weighted Average Intrinsic Value, Outstanding at end of period | $
Options Exercisable | shares	3,188,267
Weighted Average Exercise Price, Outstanding at ending of period | $ / shares	$ 5.20
Weighted Average Remaining Life, Exercisable	7 years 3 months 3 days
Weighted Average Intrinsic Value, Exercisable end of period | $	$ 3,409,891

STOCKHOLDERS' EQUITY (Details 3

STOCKHOLDERS' EQUITY (Details 3) - Common Stock Purchase Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2022
Option Indexed to Issuer's Equity [Line Items]
Outstanding at beginning of period	3,548,302
Weighted average exercise price, Outstanding at beginning of period	$ 0.73
Weighted Average remaining life, Outstanding	4 years 7 months 17 days	4 years 9 months 18 days
Granted	2,805,050
Weighted average exercise price, Granted	$ 0.65
Exercised
Weighted average exercise price, Exercised
Cancelled/Expired
Weighted average exercise price, Expired
Outstanding at end of period	6,353,352
Weighted average exercise price, Outstanding at end of period	$ 0.70

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)		2 Months Ended	3 Months Ended
	Aug. 01, 2023	Sep. 28, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Jun. 20, 2023	Mar. 31, 2023	Jun. 20, 2022	May 17, 2022	Feb. 06, 2014
Class of Stock [Line Items]
Preferred stock shares authorized			10,000,000		10,000,000
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares issued			561,010		0
Preferred stock, shares outstanding			561,010		0
Common stock, shares authorized			100,000,000		100,000,000
Common stock, par value			$ 0.0001		$ 0.0001
Common stock, shares issued			65,698,144		63,698,144
Common stock, shares outstanding			65,698,144		63,698,144
Obligation to purchase								$ 20,000,000
Number of shares issued									47,115
Common stock reserved for issuance			17,414		17,414		17,414
Common stock issued			0
Stock based compensation expense			$ 983,829	$ 1,026,008
Unrecognized compensation cost			1,305,630
Intrinsic value			$ 3,409,891
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Shares forfeited
Number of exercisable shares outstanding			3,188,267
Equity Incentive Plan 2014 [Member]
Class of Stock [Line Items]
Common stock reserved for issuance										1,206,000
Plan Options [Member]
Class of Stock [Line Items]
Option granted			5,134,285
Options available to be issued			6,047,409
Dan Drit Denmark [Member]
Class of Stock [Line Items]
Common stock, shares outstanding			167,639
Employees [Member]
Class of Stock [Line Items]
Option granted			0	350,000
Employees 1 [Member]
Class of Stock [Line Items]
Option granted			0	184,800
Shares forfeited			0	18,960
Employees 2 [Member]
Class of Stock [Line Items]
Option granted			0	73,200
Board Of Directors And Scientific Advisory Board [Member]
Class of Stock [Line Items]
Option granted			219,106	50,958
Employees 3 [Member]
Class of Stock [Line Items]
Option granted			26,000	0
Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued						696,021
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized			10,000,000		10,000,000
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock designated shares			1,000,000		0
Preferred stock, shares issued			561,010		0
Preferred stock, shares outstanding			561,010		0
Preferred Stock Issuances [Member]
Class of Stock [Line Items]
Common stock, par value	$ 7.13
Number of shares issued	280,505
Closed private placement units	280,505
aggregate proceeds	$ 2,000,000
Conversion of promissory note	$ 2,000,000
Aggregate preferred stock shares			561,010
Aggregate common stock shares			5,610,100
Warrants sold			2,805,050
Exercise price			$ 0.65
Common Stock Issuances [Member]
Class of Stock [Line Items]
Shares of common stock for consulting services		2,000,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				1 Months Ended		3 Months Ended
	Sep. 10, 2021	Feb. 06, 2020	Jul. 09, 2018	Aug. 25, 2021	Jan. 31, 2020	Sep. 30, 2023	Sep. 28, 2023	Jun. 30, 2023	Mar. 31, 2023	Nov. 15, 2019
Defined Benefit Plan Disclosure [Line Items]
Consulting expenses			$ 130,000
Up-front payment										$ 10,000,000
Payment for expenditures										$ 760,000
Initial payment				$ 600,000
Paid initial payment	$ 600,000
Remaining shares						17,414		17,414	17,414
Number of shares issued for shareholders						0
Compensation description						The Company maintains employment agreements with other staff in the ordinary course of business.
Stock Purchase Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Equity interests							100%
G Tech [Member] | License Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Payment for license		$ 1,200,000			$ 1,200,000
Royalty Percentage					2%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)			3 Months Ended
	Aug. 01, 2023	Jun. 26, 2023	Sep. 30, 2023	Sep. 30, 2022	May 17, 2022
Subsidiary, Sale of Stock [Line Items]
Shares issued					47,115
Share price per share	$ 7.13
Proceeds from private placement	$ 500,000		$ 2,000,000
Conversion of shares value	$ 2,000,000
Conversion of shares, shares	280,505
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Restricted shares			1,000,000	1,000,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued	70,126
Private Placement [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued		567,588
Proceeds from private placement		$ 300,822

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			3 Months Ended
	Oct. 10, 2023	Oct. 05, 2023	Sep. 30, 2023	Sep. 29, 2023	Sep. 05, 2023
Subsequent Event [Line Items]
Principal amount			$ 789,474	$ 789,474	$ 789,474
Maturity date			Sep. 05, 2024
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Interest rate		5%
Received gross proceeds		$ 1,250,000
Subsequent Event [Member] | Investors [Member]
Subsequent Event [Line Items]
Interest rate		5%
Principal amount		$ 1,315,789
Subsequent Event [Member] | Notes 2023 [Member]
Subsequent Event [Line Items]
Interest rate		12%
Maturity date		Sep. 05, 2024
Subsequent Event [Member] | Mr Miller [Member]
Subsequent Event [Line Items]
Restricted shares	1,000,000
Subsequent Event [Member] | Mr Miller [Member] | Vest In 2024 [Member]
Subsequent Event [Line Items]
Restricted shares	166,667
Subsequent Event [Member] | Mr Miller [Member] | Vest In 2025 [Member]
Subsequent Event [Line Items]
Restricted shares	444,444
Subsequent Event [Member] | Mr Miller [Member] | Vest In 2026 [Member]
Subsequent Event [Line Items]
Restricted shares	388,889